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A B S T R A C TObjective: Hepatitis C virus (HCV) infection is the leading cause of
liver disease, and Taiwan has among the highest prevalence of HCV
infection in the general population in Northeast Asia, estimated at
between 2% and 4%. The aim of this study was to estimate the
number of patients living with chronic HCV infection in Taiwan and
quantify the expected numbers in each of the ﬁve Metavir ﬁbrosis
stages. Methods: We applied a back-projection approach, using
observed hepatocellular carcinoma incidence between 1979 and 2008
and a smoothed Expectation-Maximization algorithm to maximize a
Poisson likelihood to estimate the previous incidence of HCV infec-
tion. The algorithm was coded in Excel and combined with the
MOdelling the NAtural histoRy and Cost-effectiveness of Hepatitis
model (a hepatitis C natural history markov model) to predict the past
and future numbers in each Metavir ﬁbrosis stage. Results: Incident
cases were predicted to have peaked in 1972 at 56,634 annually, withsee front matter Copyright & 2014, International S
r Inc.
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ndence to: Philip McEwan, Singleton Court Businesthe prevalence peaking in 1986 at 763,737 infections and falling to
578,203 infections in 2012. It was estimated that in 2012, 127,795
(23.0%), 105,545 (19.0%), 81,211 (14.6%), 123,939 (22.3%), and 116,823
(21.1%) subjects were in ﬁbrosis stages F0, F1, F2, F3, and F4,
respectively. Discussion: Our study provides HCV infection preva-
lence estimates, stratiﬁed by Metavir ﬁbrosis stage, in Taiwan for
2012. This has potential implications for budget planning, particularly
with the availability of emerging therapies because ﬁbrosis stage is
predictive of both rapid and sustained virological response; therefore,
planning expected treatment response in a given population could be
enhanced with this additional information.
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Hepatitis C virus (HCV) infection is the leading cause of liver disease
and a major public health burden; approximately 130 to 170 million
people are estimated to be infected globally [1]. Incidence rates
across the world ﬂuctuate, and accurate estimates are difﬁcult to
obtain because of the asymptomatic, often latent nature of the
disease before clinical presentation. The World Health Organization
estimates that HCV infects 3 to 4 million people every year [2]; of
these, approximately 20% to 30% will spontaneously clear the virus;
the remaining develop chronic HCV infection and are at risk of
progressing to compensated cirrhosis, decompensated cirrhosis
(DC), hepatocellular carcinoma (HCC), and premature death. Taiwan
has among the highest prevalence of HCV infection in the general
population in Northeast Asia [3], estimated at between 2% and 4%
(463,000 and 927,000) [4].
The period between infection and end-stage liver disease
(ESLD) is highly variable [5]. On average, around 10% to 20% of
the subjects with HCV infection will progress to ESLD within 10 to20 years following infection [6]. This has important implications
because the current health care burden associated with treating
HCV infection and managing ESLD complications is relatively
small compared with the potential future cost associated with
treating those progressing over the coming years. Furthermore,
as patients age and their disease progresses, the number pre-
senting either with ESLD or for treatment will increase substan-
tially. Consequently, knowledge of historic infection rates and
disease prevalence estimates is informative for developing effec-
tive public health management strategies for screening and
treatment. Estimates of the number of subjects living with
chronic HCV infection and the extent of ﬁbrosis are important
because treatment response is reduced in patients with advanced
ﬁbrosis. Identifying treatment-eligible patients and initiating the
most cost-effective treatment option will become increasingly
relevant in the very near future.
The aim of this study was to estimate the number of patients
living with chronic HCV infection in Taiwan and quantify the
expected numbers in each of the ﬁve Metavir ﬁbrosis stages.ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Back Projection
Back projection, also known as back-calculation, is a technique that
has been used extensively to estimate historic HIV infection levels
given knowledge of AIDS incidence [5]. The technique has also been
applied to estimate the incidence and prevalence of hepatitis C
infection in the United Kingdom [7], France [8], and Australia [9].
Estimating chronic HCV infection incidence and prevalence via
back projection typically uses routinely coded HCV-related ESLD
events, such as DC or HCC, together with an estimate of the time
between chronic infection and progression to ESLD to calculate the
unobserved infections that must have occurred in the past.
The technique can be implemented in a number of ways,
ranging from statistical to deterministic [10–12]. The approach
taken in this study was to use a smoothed Expectation-
Maximization algorithm to maximize a Poisson likelihood. We
assume that the incidence of chronic HCV infection cases occurs
as an independent random process in which the number of
individuals developing chronic HCV infection following infection
in period t is denoted as Nt and the number of subjects with HCV-
related HCC is denoted as Yt, where t¼1,2,…,T. In the current
implementation, T represents the last year of recorded HCC
included in the analysis (2008) and each t is equivalent to one
calendar year. The number of expected HCV-related HCC cases in
year t is given by
E YjN1,N2,…,Nt½ ¼ ∑
t
i¼1
Nif ti
The mean number of HCC cases in year t is then given by
mt¼ ∑
t
i¼1
λif t-i
where mi¼E½Yt and λi¼E½Ni
Assuming that all HCV infections are independent Poisson
variates, the log likelihood function is given by
log L λjy ¼ ∑
T
t¼1
½yt log mt
 mt
where m is given by the second equation.
The Expectation-Maximization algorithm was coded in Visual
Basic for Applications within Microsoft Excel.Fig. 1 – Incident cases of conﬁrmed HCC in Taiwan withData
Data on HCC incidence for the period 1979 to 2008 were obtained
from the Taiwan National Cancer Registration Database. Our
analysis required HCV-speciﬁc HCC event data; therefore, an
adjustment was made that accommodated secular trends in
hepatitis B virus (HBV) and HCV-associated HCC in line with
reported male- and female-speciﬁc HBV-related HCC over the
period 1981 to 2001 [4]. In men, HBV-related HCC decreased from
81.5% in the period 1981 to 1983 to 66.2% in the period 1999 to
2001. In women, HBV-related HCC decreased from 66.7% in the
period 1981 to 1983 to 41.4% in the period 1999 to 2001. We further
assumed that 10.5% (males) and 11.3% (females) of the HCC cases
were unrelated to either HBV or HCV. Figure 1 shows the unad-
justed HCC data alongside estimated HCV-speciﬁc HCC incidence
data. The upper and lower limits for estimated HCV-speciﬁc HCC
were obtained by using reported conﬁdence intervals for secular
trends in HBV-related HCC in Taiwan.
Back projection is relatively inaccurate at predicting recent
infection rates; as such, it was necessary to provide a minimum
HCV incidence within the model. Because information on HCV
incidence within Taiwan is extremely limited, the infection rate
was estimated from US data and applied to the Taiwan popula-
tion. It was estimated that 5.437 people in every 100,000 are
infected with HCV each year [13]. This rate was applied to the
Taiwan population to give an annual incidence of 1260.Model
The natural history of progression from chronic infection to HCC
was obtained by using the MOdelling the NAtural histoRy and
Cost-effectiveness of Hepatitis model. This is a cohort-based
Markov lifetime simulation that has previously been described
in detail [14]. In brief, the model iterates a cohort through annual
cycles starting at Metavir disease stage F0 (no ﬁbrosis) and
progressing though F1 (portal ﬁbrosis with no septa), F2 (portal
ﬁbrosis with few septa), F3 (portal ﬁbrosis with numerous septa),
and F4 (compensated cirrhosis). The model ﬂow diagram is
shown in Figure 2. Progression through ﬁbrosis stages is con-
trolled via stage-speciﬁc transition probabilities inﬂuenced by the
duration of HCV infection, age at infection, sex, genotype, source
of infection, and excessive alcohol consumption [15]. Table 1
reports the transition rates used in the model. We assumed that
54% of the infections were genotype 1 [3].
In addition to estimating the number of chronic HCV infection
cases (F0), the number of individuals progressing through ﬁbrosisestimated HCV-related HCC. HCV, hepatitis C virus.
Table 1 – Annual disease progression rates, distribution type, and parameters used in the model.
Disease
progression
Mean SE Distribution Parameters Source
F0 to F1 0.079 Normal* exp½2:0124 0:07589 HCVDð Þ
þ 0:3247 Design þ 0:5063Maleð Þþ 0:4839 GT1ð Þ
[15]
F1 to F2 0.073 Normal* exp 1:5387 0:06146 HCVDð Þþ 0:8001 Alchoholð Þ½  [15]
F2 to F3 0.111 Normal* exp½1:6038þ 0:0172 HCV Age  0:05939 HCVDð Þþ
0:4539 Alchoholð Þ
[15]
F3 to F4 0.051 Normal* exp½2:2898þ 0:01689 HCV Age  0:03694 HCVDð Þþ 0:5963 IDUð Þþ
1:1682 BTð Þ 0:4652 GT1ð Þ
[15]
Minimum Maximum
F3 to HCC 0.002 0.013 Normal 0.001 0.028 [16]
F4 to DC 0.030 0.010 Normal 0.010 0.050 [16]
F4 to HCC 0.017 0.014 Normal 0.008 0.045 [16]
DC to LT 0.031 0.008 Normal 0.016 0.047 [16]
DC to death 0.100 0.051 Normal 0.1 0.2 [16]
HCC to death 0.700 0.102 Normal 0.55 0.9 [16]
Alpha Beta
DC to HCC 0.079 0.011 Beta 45.583 531.417 [16]
LT (year 1) to
death
0.150 0.005 Beta 669.750 3795.250 [16]
LT (year 2þ) to
death
0.030 0.003 Beta 133.950 4331.050 [16]
Alcohol, proportion of cohort with excess alcohol consumption; BT, proportion of cohort infected via blood transfusion; DC, decompensated
cirrhosis; design, observational or trial setting; GT1, proportion of cohort genotype 1; HCC, hepatocellular carcinoma; HCV Age, age at HCV
infection; HCVD, HCV duration of infection (y); IDU, proportion of cohort infected via intravenous drug use; LT liver transplant; male,
proportion of cohort male; SE, standard error.
 SEs for coefﬁcients obtained from Thein et al. [15] (Table 6) and sampled from a normal distribution.
Fig. 2 – Flow diagram of the MONARCH model. Annual transition probabilities control progression through disease states.
HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
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Fig. 3 – Estimated cumulative number of chronic hepatitis C infections with bootstrapped 95% conﬁdence intervals. HCV,
hepatitis C virus.
Fig. 4 – Cumulative estimated prevalence of chronic HCV by ﬁbrosis stage. As of 2012, it is estimated that 23.0%, 19.0%, 14.6%,
22.3%, and 21.1% of the 555,313 patients with chronic HCV are in ﬁbrosis sages F1, F2, F3, and F4, respectively.
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incidence of HCV-related complications.Results
As of 2012, the model estimates that a cumulative total
of 1.2 million people have been chronically infected with
HCV infection in Taiwan. The initial incidence of chronic HCV
infection cases was predicted to have occurred during the late
1950s, with the most rapid period of growth in incidence
occurring during the 1960s and 1970s (Fig. 3). New cases were
predicted to have peaked in 1972 at 56,634 annually. Figure 4
shows prevalent cases stratiﬁed by ﬁbrosis stages estimated
historically over the period 1955 to 2012. These projections
assume that the natural history of disease progression is
static over time. In 2012, it was estimated that 127,795
(23.0%), 105,545 (19.0%), 81,211 (14.6%), 123,939 (22.3%), and
116,823 (21.1%) subjects were in ﬁbrosis stages F0, F1, F2, F3,
and F4, respectively.Figure 5 shows the estimated prevalence of chronic HCV
infection over time of four different scenarios. The base-case
estimate (solid line) shows the prevalence of HCV assuming a
minimum HCV incidence of 1,260. It is predicted that a peak
prevalence of 763,737 occurs in 1986, with prevalence falling to
578,203 in 2012. The other plots represent the prevalence of HCV
assuming a minimum incidence of 10,000 (vertical crosses), 5,000
(diagonal crosses), and 0 (stars). Without accurate information,
we have predicted the current incidence of HCV in Taiwan at a
constant rate of 1,260 on the basis of information from the United
States. It is clear that to accurately predict the future prevalence
of HCV, accurate estimates of current incidence are needed
because the incidence of HCV has a strong inﬂuence on future
prevalence.
Figure 6 shows the predicted incidence of DC, HCC, HCV-
related liver transplants, and deaths historically and projected
over the period 2012 to 2030. Assuming current natural history
disease progression, the incidence of subjects living with DC is
expected to increase from 3463 in 2012 to a peak of 3540 in 2015;
importantly, the model suggests that these numbers would
Fig. 5 – Estimated prevalence of chronic HCV with varying ‘minimum incidence caps.’ HCV, hepatitis C virus.
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The projected incidence of HCC similarly increases initially,
peaking at 2939 cases in 2016 and then decreasing to an
estimated 1891 cases in 2030. By 2030, it is projected that the
incidence of HCV-related liver transplants will have decreased to
384, with approximately 9000 transplants required over the
period 2012 to 2030.Discussion
This study used a contemporary HCV natural history disease
progression model to characterize the development of chronic
HCV infection to HCC, thereby enabling past infection rates to be
estimated. This study provides HCV prevalence estimates in
Taiwan for 2012 that are consistent with those previously
reported. In addition, this study provides further granularity by
partitioning those chronically infected with HCV into ﬁbrosis
stages. This has potential implications for budget planning,
particularly with the availability of emerging therapies because
ﬁbrosis stage is predictive of both rapid and sustained virological
response [17]; therefore, planning expected treatment response
in a given population should be enhanced with this additional
information. Furthermore, the step change in efﬁcacy observed
with protease inhibitors is associated with a substantial increase
in drug acquisition cost; therefore, future optimal treatment
strategies may need to consider patient phenotype, expected
sustained virological response, and therapy cost in combination
when planning budgets. Importantly, this study demonstrated
that the potential excess health care expenditure required to
manage future ESLD complications is substantial; therefore, the
value associated with successful treatment is also high. Conse-
quently, emerging HCV therapies will be both costly and highly
cost-effective.
There are inherent limitations to the modeling approach
undertaken in this analysis. Back projection requires accurate
estimates of ESLD end points. The source data used for this
analysis were HCC data drawn from the Taiwan National CancerRegistration, and it was necessary for us to estimate the percent-
age of HCC cases that were HCV speciﬁc; this is subject to
some uncertainty. Furthermore, given the latency of HCV
disease progression, back projection is unable to provide esti-
mates of recent (last 10 years) infection levels; other techniques
are required for this, for example, unlinked anonymous testing
programs. A consequence of unreliable recent infection rates
will have an insigniﬁcant effect on future projections over the
short term but may have an impact on longer-term projections.
The main objective of this approach, however, is not to provide
deﬁnitive estimates of disease burden over the long term
but rather to provide an insight into potential outcomes. The
emergence of protease inhibitors and the imminent profusion
of available therapies that have the potential to cure HCV
infection will lead to clinical outcomes very different from
those projected here. As such, our analysis is designed to
facilitate an understanding of possible future scenarios and
the clinical and economic consequences of changing clinical
practice today, or, as presented here, maintaining current
practice.
Our estimates are based on published disease progression
parameters that are consistent with the natural history of HCV
infection progression. The relatively recent uptake in the treat-
ment for HCV, with associated sustained virological response
rates, will have a very limited impact on our back-projected HCV
incidence due to the long duration between chronic HCV infec-
tion and HCV infection end points, but clearly future incidence
will be dependent on both future treatment uptake rates and
treatment efﬁcacy; consequently, our results should be inter-
preted with this limitation in mind.
Recent evidence from the United States suggests that screen-
ing and treating hepatitis C is highly cost-effective [18]; earlier
work from a UK perspective demonstrated only borderline cost-
effectiveness in screening for HCV in intravenous drug users and
universal screening was found to be not cost-effective [19]. Given
the expected costs of maintaining the current clinical practice
patterns that this study predicts, the improved efﬁcacy of newer
therapies, and the potential for a cure that would prevent
Fig. 6 – (A) Estimated prevalence of hepatocellular carcinoma and chronic HCV per year. (B) Estimated incidence of liver
transplants and liver-related deaths per year. HCC, hepatocellular carcinoma; HCV, hepatitis C virus.
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a screening strategy for Taiwan may be warranted.
Source of ﬁnancial support: This study was funded by an
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